
ADMA Biologics Faces Securities Lawsuit Over Alleged Revenue Inflation
Investors who held ADMA Biologics stock between August 9, 2024, and March 25, 2026, are being sought by The Gross Law Firm for a potential class action lawsuit. The litigation focuses on allegations that the company misled shareholders regarding its internal controls, revenue reporting, and undisclosed related party transactions.






















